Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children. (1st February 2016)

• Record Type: Journal Article
• Authors: Chokephaibulkit, K; Houillon, G; Feroldi, E; Bouckenooghe, A
• Is Part Of: Expert review of vaccines. Volume 15:Number 2(2016)
• Page Start: 153
• Page End: 166
• Publication Date: 2016-02-01
• Subjects: Japanese encephalitis -- vaccines -- IMOJEV® -- pediatrics -- flaviviridae; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1586/14760584.2016.1123097
• Languages: English
• ISSNs: 1476-0584

Abstract

ABSTRACT: JE-CV (IMOJEV®, Sanofi Pasteur, France) is a live attenuated virus vaccine constructed by inserting coding sequences of the prM and E structural proteins of the Japanese encephalitis SA14-14-2 virus into the genome of yellow fever 17D virus. Primary immunization with JE-CV requires a single dose of the vaccine. This article reviews clinical trials of JE-CV in children aged up to 6 years conducted in countries across South-East Asia. Strong and persistent antibody responses were observed after single primary and booster doses, with 97% of children seroprotected up to five years after booster vaccination. Models of long-term antibody persistence predict a median duration of protection of approximately 30 years after a booster dose. The safety and reactogenicity profiles of JE-CV primary and booster doses are comparable to other widely used childhood vaccines.